ACRS
Aclaris Therapeutics Inc
5.30$
-8.0%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +441.4% | +87.2% | +38.3% | +13.2% | -64.3% | -28.0% | +254.9% | +1.3% | -22.5% | +11.6% | -27.2% | |
| – | +463.5% | +89.2% | +19.9% | -14.1% | -53.3% | -31.4% | +256.6% | +12.9% | -44.4% | -2.3% | +20.2% | |
| – | -8.4% | +206.3% | +592.2% | -72.7% | -37.0% | -38.6% | +24.0% | +65.6% | -11.9% | -38.4% | -18.8% | |
| – | +470.6% | +89.2% | +19.9% | -19.6% | -55.3% | -27.8% | +253.6% | +13.7% | -45.3% | -4.6% | -20.1% | |
| – | – | – | – | +17.0% | +25.0% | +9.7% | -19.3% | -22.3% | -38.4% | +6.7% | +1,650.0% | |
| – | – | – | – | – | +527.8% | – | – | – | – | – | – | |
| – | -30.1% | +33.6% | +348.9% | +5.9% | +215.0% | -77.0% | -19.3% | -17.7% | – | – | – | |
| – | – | – | – | +0.0% | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | +892.7% | -90.1% | -1.1% | -1.1% | -1.1% | -96.1% | – | – | |
| – | -95.9% | +324.1% | +176.7% | +231.2% | -53.0% | +16.7% | +62.6% | +5.8% | -29.4% | +61.0% | -11.4% | |
| – | +7.2% | +300.2% | +105.1% | +114.2% | -18.0% | -33.7% | +54.2% | -4.3% | +41.1% | +2.1% | -9.3% | |
| – | – | – | – | +0.0% | +348.6% | -5.3% | +14.9% | -1.3% | -37.7% | +125.8% | -42.7% | |
| – | -35.9% | +251.2% | +174.9% | +49.3% | -15.1% | -47.0% | +90.0% | +3.7% | -14.2% | -47.2% | +180.6% | |
| – | – | – | – | +11,361.3% | – | – | – | – | – | – | – | |
| – | – | +83.2% | +32.9% | -4.5% | -67.5% | -46.1% | +424.1% | +0.1% | -20.5% | -1.0% | -33.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +74.7% | +15.0% | +31.2% | +17.1% | +25.6% | +2.9% | +33.4% | +15.0% | +7.0% | +10.7% | +58.7% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.